Galux, a South Korean biotechnology company, has announced the successful closing of a $29 million Series B funding round to accelerate the development of its AI-driven de novo antibody design platform. The investment will support the company’s mission to revolutionize drug discovery by leveraging advanced artificial intelligence to create novel therapeutic proteins from scratch. The funding comes at a pivotal moment in the biotech industry, as AI-powered approaches to protein design gain momentum in the race to develop targeted, effective treatments for complex diseases. Galux’s platform uses machine learning models trained on vast biological datasets to predict and design high-performance antibodies with precision, significantly reducing the time and cost traditionally associated with early-stage drug development. The company’s technology enables the generation of fully synthetic antibodies tailored to specific disease targets, bypassing the limitations of conventional methods that rely on natural immune responses. This capability opens new pathways for treating conditions such as cancer, autoimmune disorders, and rare genetic diseases where existing therapies are limited or ineffective. Galux’s leadership team emphasized that the new capital will be used to expand its AI infrastructure, deepen scientific research, and advance multiple pipeline candidates into preclinical and clinical development. The company also plans to strengthen its collaborations with academic institutions and pharmaceutical partners to validate and scale its platform. The Series B round was led by a consortium of international investors, including venture capital firms with strong track records in both biotechnology and AI innovation. The participation of these strategic backers underscores growing confidence in Galux’s ability to deliver transformative solutions in the rapidly evolving field of AI-driven drug discovery. With this funding, Galux aims to establish itself as a key player in the next generation of biopharmaceutical innovation, combining deep biological expertise with cutting-edge artificial intelligence to bring life-changing therapies to patients faster than ever before.